| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF) |
| Brand | Odefsey® |
| Indication | For the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml. |
| Assessment Process | |
| Rapid review commissioned | 28/06/2016 |
| Rapid review completed | 11/07/2016 |
| Rapid review outcome | Reimbursement Not Recommended |
4th October 2016 – The NCPE has recommended reimbursement following a re-submission of updated clinical evidence.
